Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells
- 1 March 2005
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 288 (3) , E573-E584
- https://doi.org/10.1152/ajpendo.00454.2004
Abstract
Serum levels of the adrenal androgen dehydroepiandrosterone (DHEA) peak in men and women in the third decade of life and decrease progressively with age. Increasing numbers of middle-aged and older individuals consume over-the-counter preparations of DHEA, hoping it will retard aging by increasing muscle and bone mass and strength, decreasing fat, and improving immunologic and neurobehavioral functions. Because DHEA can serve as a precursor to more potent androgens and estrogens, like testosterone (T), dihydrotestosterone (DHT), and 17β-estradiol (E2), supplemental DHEA use may pose a cancer risk in patients with nascent or occult prostate cancer. The steroid-responsive human LNCaP prostate cancer cells, containing a functional but mutated androgen receptor (AR), were used to compare effects of DHEA with those of T, DHT, and E2 on cell proliferation and protein and/or gene expression of AR, prostate-specific antigen (PSA), IGF-I, IGF-I receptor (IGF-IR), IGF-II, IGF-binding proteins-2, -3, and -5, (IGFBPs-2, -3, and -5), and estrogen receptor-β (ERβ). Cell proliferation assays revealed significant stimulation by all four steroids. DHEA- and E2-induced responses were similar but delayed and reduced compared with that of T and DHT. All four hormones increased gene and/or protein expression of PSA, IGF-IR, IGF-I, and IGFBP-2 and decreased that of AR, ERβ, IGF-II, and IGFBP-3. There were no significant effects of hormone treatment on IGFBP-5 mRNA. DHEA and E2 responses were similar, and distinct from those of DHT and T, in time- and dose-dependent studies. Further studies of the mechanisms of DHEA effects on prostate cancer epithelial cells of varying AR status, as well as on prostate stromal cells, will be required to discern the implications of DHEA supplementation on prostatic health.Keywords
This publication has 47 references indexed in Scilit:
- Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young menFertility and Sterility, 2004
- Androgen Receptor Regulation by Physiological Concentrations of the Isoflavonoid Genistein in Androgen-Dependent LNCaP Cells Is Mediated by Estrogen Receptor βEuropean Urology, 2003
- Insulin-like growth factor II and androgen receptor expression in the prostateBJU International, 2001
- Molecular expression of 17βhydroxysteroid dehydrogenase types in relation to their activity in intact human prostate cancer cellsMolecular and Cellular Endocrinology, 1997
- P450-dependent enzymes as targets for prostate cancer therapyThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate CancerNew England Journal of Medicine, 1995
- Widespread tissue distribution of steroid sulfatase, 3β-hydroxysteroid dehydrogenase/Δ5-Δ4isomerase(3β-HSD), 17β-HSD5α-reductase and aromatase activities in the rhesus monkeyMolecular and Cellular Endocrinology, 1994
- The IGF Axis in the ProstateHormone and Metabolic Research, 1994
- The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Enzymes of Androgen Formation and Degradation in the Human ProstateAnnals of the New York Academy of Sciences, 1990